Skip to main content
. 2024 Oct 2;15(10):1296. doi: 10.3390/genes15101296

Figure 2.

Figure 2

Relative expression of HMGB1 and TGF-β1 in MI patients’ PBMCs, according to the occurrence of adverse LV remodeling six-months-post-MI, based on the >20% increase in LVEDV: (A) significant upregulation of HMGB1 mRNA was detected in patients’ PBMCs with adverse remodeling (N = 18) compared to patients without adverse remodeling (N = 77) (0.046 ± 0.018 vs. 0.036 ± 0.013, p = 0.04); (B) TGF-β1 mRNA expression was not significantly different between patients with adverse remodeling and patients without adverse remodeling (0.565 ± 0.173 vs. 0.497 ± 0.148, p = 0.15); (C) BIRC3 mRNA expression did not differ significantly between patients with adverse remodeling and patients without adverse remodeling (0.013 ± 0.005 vs. 0.014 ± 0.007, p = 0.48); (D) ADAM17 mRNA expression did not differ significantly between the two patient groups (adverse LVR: 0.009 ± 0.002 vs. without adverse LVR: 0.009 ± 0.005, p = 0.15); (E) CDKN1A mRNA expression was not significantly different between patients with adverse remodeling and patients without adverse remodeling (0.031 ± 0.014 vs. 0.027 ± 0.017, p = 0.22); (F) FTO mRNA expression did not differ significantly between patients with adverse remodeling and patients without adverse remodeling (0.006 ± 0.003 vs. 0.005 ± 0.002, p = 0.14). * p < 0.05. ns: no significance.